Saturday 17 October 2026
Export JAGX’s income statement to Excel — free account
Jaguar Animal Health, Inc.
JAGX Healthcare Biotechnology
Jaguar Animal Health, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $11.5 million, down 1.52% from fiscal 2024. In the quarter to June 2026, revenue fell 58.9%, EPS grew 95.6%, free cash flow grew 13.8% and total debt fell 83.9%, each against the same quarter a year earlier.
3.53
1.06
−23.09%
Follow JAGX
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
4 | 4 | 3 | 5 |
+8 more TTM periods Free account |
| (1,125.38%) | 671.84% | 729.95% | (538.24%) | ||
| (127.14%) | (112.78%) | (116.79%) | (74.66%) | ||
ROIC |
(28,393.64%) | 0.00% | 0.00% | (241.91%) | |
Return on Tangible Assets |
705.52% | 249.97% | 269.95% | 646.03% | |
Average Days of Receivables |
2.60 | 3.46 | 53.84 | 46.58 | |
Free Cash Flow per Share |
(123.80) | (219.24) | (5,396.14) | (9,191.03) | |
Free Cash Flow |
(6.68) | (7.54) | (23.74) | (26.65) | |
Capital Expenditures |
— | — | (0.06) | (0.63) | |
| Other line items | |||||
Cash ROIC |
(50.50%) | (140.00%) | (561.70%) | (171.58%) | |
Accounts Receivable Turnover |
36.74 | 35.43 | 6.88 | 8.39 | |
Accounts Payable Turnover |
0.86 | 0.74 | 0.54 | 0.33 | |
Inventory Turnover |
0.55 | 0.48 | 0.40 | 0.21 | |
Average Days of Payables |
355.51 | 409.62 | 840.06 | 1,446.13 | |
Days of Inventory on Hand |
542.64 | 646.13 | 831.65 | 1,820.38 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
90.72% | 85.10% | 216.89% | 128.87% | |
Selling, General and Administrative Expense of Revenue |
81.80% | 86.22% | 242.19% | 231.57% | |
Share Based Compensation of Revenue |
2.07% | 2.32% | 7.22% | 9.30% | |
Interest Coverage |
(25.95) | (32.00) | (685.19) | 187.56 | |
Operating CF/Net income |
0.13 | 0.15 | 0.44 | 0.65 | |
Depreciation/Fixed assets |
6.59 | 5.51 | 5.09 | 4.66 | |
Capex/Depreciation |
0.00 | 0.00 | (0.02) | (0.28) | |
Revenue per Share |
515.09 | 859.56 | 2,616.14 | 4,063.79 | |
Operating CF per Share |
(123.80) | (219.24) | (5,383.18) | (8,973.79) | |
Capex per Share |
0.00 | 0.00 | (12.95) | (217.24) | |
Capex to Sales |
0.00 | 0.00 | 0.01 | 0.05 |
Columns are period end dates · fundamentals updated 2 Oct 2026